Jazz Pharmaceuticals JAZZ Rylaze — Total revenues
Discontinued — last reported Q4 '23
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 28, 2024, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's rylaze — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's rylaze — total revenues?
- Jazz Pharmaceuticals (JAZZ) reported rylaze — total revenues of $101.75M in Q4 2023.
- How has Jazz Pharmaceuticals's rylaze — total revenues changed year-over-year?
- Jazz Pharmaceuticals's rylaze — total revenues increased by 25.7% year-over-year, from $80.97M to $101.75M.
- What is the long-term trend for Jazz Pharmaceuticals's rylaze — total revenues?
- Over 2 years (2021 to 2023), Jazz Pharmaceuticals's rylaze — total revenues has grown at a 114.6% compound annual growth rate (CAGR), from $85.63M to $394.23M.
- What does rylaze — total revenues mean?
- The total sales revenue generated by the specific oncology drug Rylaze.
- How do you interpret rylaze — total revenues?
- An increase indicates successful market penetration, expanded patient access, or increased clinical adoption of the therapy, while a decrease may signal competitive pressure, patent expiration, or changes in clinical treatment guidelines.
- How does rylaze — total revenues compare across companies?
- Comparable to product-specific revenue lines reported by other biopharmaceutical companies, such as sales of individual oncology or rare disease therapies.